In this interview Ira Zackon, MD, highlights data on bispecific antibody use in patients with multiple myeloma in the community setting as presented at ASH 2025.

In this interview Shahzad Raza, MD, discusses a study on the treatment of patients with extramedullary myeloma, as presented at ASH 2025.

Lewiss on Lifestyle MedicineThe U.S. physical activity guidelines recommend that healthy adults, including elderly, get at least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of ...

In this interview Shahzad Raza, MD, highlights data on CAR T-cell therapies and the use of bispecifics in earlier lines of multiple myeloma as presented at ASH 2025.

In this interview, Ann S. LaCasce, MD, highlights a late-breaking abstract on in vivo CAR T-cell therapy use in multiple myeloma, as presented at ASH 2025.

Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...

ORLANDO — Children and adolescents with food allergy often experience substantial fear of negative social evaluation, ...

Calling eye drops “artificial tears” can mislead people into thinking the drops are more sophisticated than they truly are ...

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Self-reported knee crepitus may predict osteoarthritis 1 year following ACL reconstruction, according to findings published ...

Autoantibody positivity rates were lower in people with dermatomyositis who used immunostimulatory herbs before disease onset ...